Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics

CDC scientists have developed recombinant flavivirus nucleic acids for the generation of broad protective immunity against flaviviruses, as well as the development of sensitive serologic diagnostic tools. Mosquito borne viral encephalitis is often caused by a flavivirus, such as Japanese encephalitis virus, dengue virus or West Nile virus. Infection by these pathogens is often lethal to both humans and animals.

Specifically, these novel recombinant nucleic acids encode critical structural proteins of flaviviruses, such as yellow fever virus. The invention provides for a method of immunizing a subject against infection by a number of pathogenic flaviviruses. Furthermore, generated antigenic subviral particles can also serve as a tool for the development of specific, antibody detection-based flavivirus diagnostic assays.

Potential Commercial Applications: Competitive Advantages:
  • Development of a broadly useful commercial vaccine for pathogenic flaviviruses
  • Insect-borne disease monitoring and surveillance programs
  • Generated antigen can be used for high-specificity serologic diagnostic assays
  • In vivo animal studies demonstrate specific antibody generation and complete protection
  • Desired immune response provided by a single intramuscular injection in both murine and equine studies
  • Potential for vaccine use and the development of commercial flavivirus infection diagnostic assays and kits

Development Stage:
  • In vitro data available
  • In vivo data available (animal)

Related Invention(s):


Gwong-Jen Chang (CDC)  ➽ more inventions...

Intellectual Property:
US Pat: 7,417,136 issued 2008-08-26
PCT Pat: 8,105,609 issued 2012-01-31
US Pat: 8,728,488 issued 2014-05-20
US Application No. 12/122,330 filed on 2008-05-16
US Application No. 13/338,529 filed on 2011-12-28
US Application No. 60/087,908 filed on 1998-06-04
Various international patent applications pending or issued

Chang GJ, et al. PMID 11797784
Chang GJ, et al. PMID 10756038

Licensing Contact:
Jeremiah Mitzelfelt,
Phone: 301-443-8518

OTT Reference No: E-341-2013-0
Updated: Jan 28, 2014